XML 52 R32.htm IDEA: XBRL DOCUMENT v3.7.0.1

Commitments and Contingencies - Additional Information (Detail)	1 Months Ended			3 Months Ended		6 Months Ended		12 Months Ended
	Dec. 31, 2015 USD ($)	Nov. 30, 2015 USD ($) shares	Jan. 31, 2015	Jun. 30, 2017 USD ($) Amendments	Jun. 30, 2016 USD ($)	Jun. 30, 2017 USD ($) Amendments Milestone	Jun. 30, 2016 USD ($) Milestone	Dec. 31, 2015 USD ($)
Other Commitments [Line Items]
Rental expense				$ 141,000	$ 46,000	$ 182,000	$ 105,000
Number of milestones achieved | Milestone						0	0
Indemnification obligations amount				0		$ 0
Contingent liabilities				$ 0		$ 0
License Agreement [Member]
Other Commitments [Line Items]
Sales based milestone payment	$ 36,000,000							$ 36,000,000
Royalty payment period	8 years
License Agreement [Member] | Maximum [Member]
Other Commitments [Line Items]
Development and regulatory milestone payments	$ 42,100,000							42,100,000
License Agreement [Member] | Minimum [Member]
Other Commitments [Line Items]
Sales required to achieve milestone payment	1,000,000,000
Office of Chief Scientist [Member]
Other Commitments [Line Items]
Grants received	537,000							537,000
Scientific Development and Research, Inc. and Otodyne, Inc. [Member] | License Agreement [Member]
Other Commitments [Line Items]
License fees paid		$ 700,000
Share issued as consideration | shares		9,780
UMB [Member] | Master License Agreement [Member]
Other Commitments [Line Items]
Number of amendments | Amendments				4		4
Annual maintenance fee						$ 10,000
Percentage of non-royalty sub license income						10.00%
UMB [Member] | Master License Agreement [Member] | Minimum [Member]
Other Commitments [Line Items]
Annual royalty						$ 50,000
UMB [Member] | Master License Agreement [Member] | IND [Member] | Upon Filing IND Application For Licensed Product [Member]
Other Commitments [Line Items]
Milestone payment						50,000
UMB [Member] | Master License Agreement [Member] | IND [Member] | Upon FDA Approval [Member]
Other Commitments [Line Items]
Milestone payment						100,000
UMB [Member] | Master License Agreement [Member] | Investigational Drug Application Non Prostate Disease [Member] | Maximum [Member]
Other Commitments [Line Items]
Aggregate milestone payments associated with development of licensed product						$ 150,000
Johns Hopkins [Member] | License Agreement [Member]
Other Commitments [Line Items]
Percentage of non-royalty sub license income			20.00%
Potential milestone payments under license agreement								700,000
Milestone payments expensed during period								50,000
Additional liabilities for milestone payments	$ 0							0
Johns Hopkins [Member] | License Agreement [Member] | Research and Development [Member]
Other Commitments [Line Items]
Upfront payment								75,000
Johns Hopkins [Member] | License Agreement [Member] | Minimum [Member]
Other Commitments [Line Items]
Annual royalty								$ 30,000

X

- Definition

Additional Milestone Payments

+ References

No definition available.

+ Details

Name:	nvus_AdditionalMilestonePayments
Namespace Prefix:	nvus_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Aggregate milestone payments.

+ References

No definition available.

+ Details

Name:	nvus_AggregateMilestonePayments
Namespace Prefix:	nvus_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Contingent liability.

+ References

No definition available.

+ Details

Name:	nvus_ContingentLiability
Namespace Prefix:	nvus_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Grants received.

+ References

No definition available.

+ Details

Name:	nvus_GrantsReceived
Namespace Prefix:	nvus_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Liabilities for additional milestone payment.

+ References

No definition available.

+ Details

Name:	nvus_LiabilitiesForAdditionalMilestonePayment
Namespace Prefix:	nvus_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Cost related to licensed technology.

+ References

No definition available.

+ Details

Name:	nvus_LicenseMaintenanceFees
Namespace Prefix:	nvus_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Milestone payments expensed during period.

+ References

No definition available.

+ Details

Name:	nvus_MilestonePaymentsExpensedDuringPeriod
Namespace Prefix:	nvus_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Number Of Amendments

+ References

No definition available.

+ Details

Name:	nvus_NumberOfAmendments
Namespace Prefix:	nvus_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

X

- Definition

Number of milestones achieved.

+ References

No definition available.

+ Details

Name:	nvus_NumberOfMilestonesAchieved
Namespace Prefix:	nvus_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Percentage of non royalty sub license income.

+ References

No definition available.

+ Details

Name:	nvus_PercentageOfNonRoyaltySubLicenseIncome
Namespace Prefix:	nvus_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Represents the maximum amount of potential milestone payments under the license agreement.

+ References

No definition available.

+ Details

Name:	nvus_PotentialMaximumMilestoneFees
Namespace Prefix:	nvus_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Regulatory milestone payments obligation.

+ References

No definition available.

+ Details

Name:	nvus_RegulatoryMilestonePaymentsObligation
Namespace Prefix:	nvus_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Royalty payments period.

+ References

No definition available.

+ Details

Name:	nvus_RoyaltyPaymentsPeriod
Namespace Prefix:	nvus_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Sales milestones payments obligation.

+ References

No definition available.

+ Details

Name:	nvus_SalesMilestonesPaymentsObligation
Namespace Prefix:	nvus_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Sales required to trigger milestone.

+ References

No definition available.

+ Details

Name:	nvus_SalesRequiredToTriggerMilestone
Namespace Prefix:	nvus_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Represents the amount of the upfront license fees.

+ References

No definition available.

+ Details

Name:	nvus_UpfrontLicenseFees
Namespace Prefix:	nvus_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

The current carrying amount of the liability for the freestanding or embedded guarantor's obligations under the guarantee or each group of similar guarantees.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 460
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=82913245&loc=d3e12069-110248

+ Details

Name:	us-gaap_GuaranteeObligationsCurrentCarryingValue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.

+ References

No definition available.

+ Details

Name:	us-gaap_LeaseAndRentalExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Costs incurred and are directly related to generating license revenue. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.2(e))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688

+ Details

Name:	us-gaap_LicenseCosts
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_OtherCommitmentsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.3)
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688

+ Details

Name:	us-gaap_RoyaltyExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Number of new stock issued during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

+ Details

Name:	us-gaap_StockIssuedDuringPeriodSharesNewIssues
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

X

- Details

Name:	us-gaap_OtherCommitmentsAxis=nvus_LicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_RangeAxis=us-gaap_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_RangeAxis=us-gaap_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_CounterpartyNameAxis=nvus_OcsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_CounterpartyNameAxis=nvus_LicensorsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_CounterpartyNameAxis=nvus_UmbMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_OtherCommitmentsAxis=nvus_MasterLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ProductOrServiceAxis=nvus_InvestigationalDrugApplicationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=nvus_UponFilingIndApplicationForLicensedProductMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=nvus_UponFdaApprovalMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ProductOrServiceAxis=nvus_InvestigationalDrugApplicationNonProstateDiseaseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_CounterpartyNameAxis=nvus_JohnsHopkinsUniversityMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: